Gold Tumbles Below $4,400 on NFP Shock: Fed Easing Bets Crater, Sell on Rallies to $4,300 
Trump Says Anthropic No Longer Seen as National Security Threat 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Goldman Sachs Sees U.S. Dollar Holding Firm as Strong Economic Data Supports Outlook 
Goldman Sachs: US Dollar Likely to Stay Strong Despite Oil Price Retreat 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
JPMorgan has reinstated coverage and price targets on 14 major biotechnology companies, signaling renewed confidence in the biotech sector as firms transform successful drug pipelines into profitable commercial businesses. According to analysts led by Jessica Fye, the industry is approaching a major “inflection point,” driven by improving profitability, expanding product portfolios, and upcoming clinical catalysts.
The investment bank highlighted several biotech companies that have already reached sustained profitability, including Alnylam Pharmaceuticals, BeOne Medicines, and Ascendis Pharma. Meanwhile, Insmed and Ionis Pharmaceuticals are expected to achieve profitability soon, creating opportunities for stronger margins and long-term revenue growth.
JPMorgan also emphasized the growing diversification strategies among biotech firms. Vertex Pharmaceuticals is expanding beyond its core business into renal disease treatments, while BioMarin continues strengthening its rare disease pipeline through acquisitions. Moderna is broadening the use of its mRNA technology into oncology despite ongoing financial concerns surrounding the company.
The report pointed to multiple upcoming clinical trial updates that could boost investor sentiment across the biotechnology market. Analysts expect major cardiovascular outcomes data related to Ionis-partnered therapies and important renal disease readouts from Vertex Pharmaceuticals to act as key catalysts over the next year.
JPMorgan assigned “Overweight” ratings to several biotech stocks, including Vertex Pharmaceuticals, Alnylam, BeOne Medicines, United Therapeutics, Insmed, Ascendis Pharma, Jazz Pharmaceuticals, Ionis, BioMarin, and Mirum Pharmaceuticals. Meanwhile, BioNTech, Incyte, and Halozyme received “Neutral” ratings. Moderna was rated “Underweight” due to concerns over financial risks despite progress in cancer research and mRNA development.
The bank also released updated price targets for December 2026. Vertex received a target of $515, Alnylam $420, BeOne Medicines $415, United Therapeutics $685, and Insmed $180. Moderna’s target was set at $40, while BioNTech received a $100 target.
JPMorgan believes the biotech sector is entering a period of durable expansion as companies scale beyond dependence on single products and continue building diversified, profitable healthcare franchises.
